An order mistakenly filed publicly in Exelixis Inc.'s patent-infringement dispute over Teva Pharmaceutical Industries Ltd.'s proposed copy of its blockbuster cancer drug Cabometyx revealed details of a longer runway for the potential launch of Teva’s cheaper version of the treatment.
A lot is riding on a federal judge’s pending decision after Exelixis’ May infringement trial against MSN Laboratories Private Ltd. in the US District Court for the District of Delaware. The 30-month regulatory delay on the US Food and Drug Administration’s approval of MSN’s proposed copy expires Nov. 5, and an Exelixis loss before then could accelerate the erosion of ...
